Biocartis and Hospital del Mar Join Forces
News Oct 21, 2013
Biocartis and Hospital del Mar have announced their license agreement on the EGFR biomarker for colon cancer.
This agreement enables Biocartis to develop a new colon cancer test, whereby a specific EGFR mutation can be rapidly and accurately detected in patients, which will enable doctors to recommend personalized therapy.
Innovative platforms and tests for cancer diagnosis
Biocartis is active in molecular diagnostics and develops innovative diagnostic platforms, which allow for efficient disease detection. Biocartis also develops a wide range of clinically relevant tests for various therapeutic areas with a primary focus on cancer diagnosis.
EGFR: new biomarker for colon cancer
Recently Dr Montagut and her team (Dr Albanell’s department of Medical Oncology, Hospital del Mar) showed that colon cancer patients with an S492R-mutation in the EGFR (Epidermal Growth Factor Receptor) can’t be helped with the colon cancer drug cetuximab.
The EGFR mutation makes the tumours resistant to this treatment, whilst they remain sensitive to treatment with panitumumab. These results were published in the leading scientific journal Nature Medicine.
Rapid diagnosis results in personalized therapy
"Our agreement with Biocartis represents a crucial step in translating our relevant scientific findings to benefit the patient,” according to Clara Montagut, associated doctor, Oncology department, Hospital del Mar and researcher at the IMIM (Hospital del Mar Medical Research Institute).
The collaboration with Hospital del Mar enables Biocartis to develop a colon cancer test for a fast and accurate detection of the EGFR mutation.
"This new biomarker enables us to develop a unique combination of tests for the detection of colon cancer, which can be analyzed on our state-of-the-art molecular diagnostic platforms," added Geert Maertens, Chief Scientific Officer at Biocartis.
Maertens continued, “The detection of this biomarker in colon cancer patients ensures that personalized therapy can be applied faster and more efficiently.”
New Blood and Urine Tests Indicate Autism in ChildrenNews
New tests, developed by researchers at the University of Warwick, could lead to earlier diagnosis of the condition.READ MORE
Specific Set of Nerve Cells Controls Seizures’ Spread Through BrainNews
This discovery could lead to new and better treatments for epilepsy.READ MORE
Comments | 0 ADD COMMENT
Next Gen Regenerative Medicine & Tissue Engineering
May 29 - May 30, 2018